Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 7/2009

01-07-2009 | Brief Report

Bovine immunodeficiency virus: identification of a long terminal repeat sequence with enhanced promoter activity

Authors: M. Cojocariu, M.-C. St-Louis, D. Archambault

Published in: Archives of Virology | Issue 7/2009

Login to get access

Abstract

We previously identified a new bovine immunodeficiency virus (BIV) trans-activator factor of transcription (Tat236) that was derived from a variant of BIV. Here, we report a new BIV long terminal repeat (LTR) sequence (LTRn) that was obtained by PCR from the DNA of cells infected with the BIV variant mentioned above. Sequence analysis indicated that the LTRn U3 region harbors three nucleic acid mutations at residue positions −194, −135 and −114 when compared to the original (wild-type) LTR sequence. Reporter gene assays indicated that LTRn promotes basal and Tat-mediated transactivation activity to levels significantly higher than those obtained with the wild-type LTR. Restoration experiments to the wild-type genotype indicated that both the −135 and −114 nucleic acid substitutions were responsible for the enhanced promoter activity of BIV LTRn.
Literature
1.
Bassuk AG, Anandappa RT, Leiden JM (1997) Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. J Virol 71:3563–3573PubMed
2.
Bouillant AM, Ruckerbauer GM, Nielsen KH (1989) Replication of the bovine immunodeficiency-like virus in diploid and aneuploid cells: permanent, latent and virus-productive infections in vitro. Res Virol 140:511–529PubMedCrossRef
3.
Carpenter S, Nadin-Davis SA, Wannemuehler Y, Roth JA (1993) Identification of transactivation-response sequences in the long terminal repeat of bovine immunodeficiency-like virus. J Virol 67:4399–4404PubMed
4.
Chirmule N, Pahwa S (1996) Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions. Microbiol Rev 60:386–406PubMed
5.
Fong SE, Pallansch LA, Mikovits JA, Lackman-Smith CS, Ruscetti FW, Gonda MA (1995) Cis-acting regulatory elements in the bovine immunodeficiency virus long terminal repeat. Virology 209:604–614PubMedCrossRef
6.
Fong SE, Greenwood JD, Williamson JC, Derse D, Pallansch LA, Copeland T, Rasmussen L, Mentzer A, Nagashima K, Tobin G, Gonda MA (1997) Bovine immunodeficiency virus tat gene: cloning of two distinct cDNAs and identification, characterization, and immunolocalization of the tat gene products. Virology 233:339–357PubMedCrossRef
7.
Garvey KJ, Oberste MS, Elser JE, Braun MJ, Gonda MA (1990) Nucleotide sequence and genome organization of biologically active proviruses of the bovine immunodeficiency-like virus. Virology 175:391–409PubMedCrossRef
8.
Gonda MA, Luther DG, Fong SE, Tobin GJ (1994) Bovine immunodeficiency virus: molecular biology and virus-host interactions. Virus Res 32:155–181PubMedCrossRef
9.
Golub EI, Li GG, Volsky DJ (1990) Differences in the basal activity of the long terminal repeat determine different replicative capacities of two closely related human immunodeficiency virus type 1 isolates. J Virol 64:3654–3660PubMed
10.
Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41:95–98
11.
Hiebenthal-Millow K, Greenough TC, Bretttler DB, Schindler M, Wildum S, Sullivan JL, Kirchhoff F (2003) Alterations in HIV-1 LTR promoter activity during AIDS progression. Virology 317:109–118PubMedCrossRef
12.
Hua J, Caffrey JJ, Cullen BR (1996) Functional consequences of natural sequence variation in the activation domain of HIV-1 Rev. Virology 15:423–429CrossRef
13.
Krebs FC, Mehrens D, Pomeroy S, Goodenow MM, Wigdahl B (1998) Human immunodeficiency virus type 1 long terminal repeat quasispecies differ in basal transcription and nuclear factor recruitment in human glial cells and lymphocytes. J Biomed Sci 5:31–44PubMedCrossRef
14.
Krebs FC, Hogan TH, Quiterio S, Gartner S, Wigdahl B (2001) Lentiviral LTR-directed expression, sequence variation, and disease Pathogenesis. In: Kuiken C, Foley B, Hahn B, Marx P, McCutchan F, Mellors JW, Wolinsky S, Korber B (eds) HIV Sequence Compendium.. Published by Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, LA-UR 02-2877
15.
Mansky LM (1998) Retrovirus mutation rates and their role in genetic variation. J Gen Virol 79:1337–1345PubMed
16.
Martins LP, Chenciner N, Asjo B, Meyerhans A, Wain-Hobson S (1991) Independent fluctuation of human immunodeficiency virus type 1 rev and gp41 quasispecies in vivo. J Virol 65:4502–4507PubMed
17.
Maury WR, Thompson J, Jones Q, Bradley S, Denke T, Baccam P, Smazik M, Oaks JL (2005) Evolution of the equine infectious anemia virus long terminal repeat during the alteration of cell tropism. J Virol 79:5653–5664PubMedCrossRef
18.
Oberste MS, Greenwood JD, Gonda MA (1991) Analysis of the transcription pattern and mapping of the putative rev and env splice junctions of bovine immunodeficiency-like virus. J Virol 65:3932–3937PubMed
19.
Overbaugh J, Bangham CRM (2001) Selection forces and constraints on retroviral sequence variation. Science 292:1106–1109PubMedCrossRef
20.
Péloponse JMJ Jr, Collette Y, Grégoire C, Bailly C, Campese D, Meurs EF, Olive D, Loret EP (1999) Full peptide synthesis, purification, and characterization of six Tat variants: differences observed between HIV-1 isolates from Africa and other continents. J Biol Chem 274:11473–11478CrossRef
21.
Serra C, Mameli G, Biolchini A, Ziccheddu M, Curreli S, Arru G, Dolei A (2002) Characterization of an HIV type 1 strain with preferential replication in adherent cells. AIDS Res Hum Retrovir 18:641–647PubMedCrossRef
22.
St-Louis M-C, Cojocariu M, Archambault D (2004) The molecular biology of the bovine immunodeficiency virus: a comparison with other lentiviruses. Animal Health Res Rev 5:125–143CrossRef
23.
St-Louis M-C, Abed Y, Archambault D (2005) The bovine immunodeficiency virus (BIV): cloning of a tat/rev cDNA encoding a novel Tat protein with enhanced transactivation activity. Arch Virol 150:1529–1547PubMedCrossRef
24.
Valter MM, Hügel A, Su Huang H-J, Cavenee WK, Wiestler OD, Pietsch T, Nicolas W (1999) Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. Cancer Res 59:5608–5614PubMed
25.
Zhang MJ, Dayton AI (1998) Tolerance of diverse amino acid substitutions at conserved positions in the nuclear export signal (NES) of HIV-1 Rev. Biochem Biophys Res Commun 243:113–116PubMedCrossRef
Metadata
Title
Bovine immunodeficiency virus: identification of a long terminal repeat sequence with enhanced promoter activity
Authors
M. Cojocariu
M.-C. St-Louis
D. Archambault
Publication date
01-07-2009
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 7/2009
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-009-0411-z

Other articles of this Issue 7/2009

Archives of Virology 7/2009 Go to the issue

Original Article

Establishment of cell lines using a doxycycline-inducible gene expression system to regulate expression of hepatitis B virus X protein

Brief Report

Seroprevalence and molecular epidemiology of enterovirus 71 in Germany

Annotated Sequence Record

Complete genome sequence of a Tobacco necrosis virus D isolate from olive trees

Original Article

Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptors

Original Article

MDV-1 VP22: a transporter that can selectively deliver proteins into cells

Annotated Sequence Record

Genomic sequence of a Japanese encephalitis virus isolate from southern China
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits